Trials challenging HIV drug doses could usher in huge cost cuts.
Monica
M
Heger
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use*; D048588:Benzoxazines / Q000008:administration & dosage / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000191:economics* / Q000821:virology; D006801:Humans
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; C098320:efavirenz